Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 130

1.

Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.

Ting RD, Keech AC, Drury PL, Donoghoe MW, Hedley J, Jenkins AJ, Davis TM, Lehto S, Celermajer D, Simes RJ, Rajamani K, Stanton K; FIELD Study Investigators.

Diabetes Care. 2012 Feb;35(2):218-25. doi: 10.2337/dc11-1109. Epub 2011 Dec 30.

PMID:
22210576
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators.

Lancet. 2005 Nov 26;366(9500):1849-61. Erratum in: Lancet. 2006 Oct 21;368(9545):1415. Lancet. 2006 Oct 21;368(9545):1420.

PMID:
16310551
[PubMed - indexed for MEDLINE]
3.

Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study.

Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, Jenkins AJ, O'Connell RL, Whiting MJ, Glasziou PP, Simes RJ, Kesäniemi YA, Gebski VJ, Scott RS, Keech AC; Fenofibrate Intervention and Event Lowering in Diabetes Study investigators.

Diabetologia. 2011 Feb;54(2):280-90. doi: 10.1007/s00125-010-1951-1. Epub 2010 Nov 4.

PMID:
21052978
[PubMed - indexed for MEDLINE]
4.

Effects of combination lipid therapy in type 2 diabetes mellitus.

ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP.

N Engl J Med. 2010 Apr 29;362(17):1563-74. doi: 10.1056/NEJMoa1001282. Epub 2010 Mar 14. Erratum in: N Engl J Med. 2010 May 6;362(18):1748.

PMID:
20228404
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy.

Forsblom C, Hiukka A, Leinonen ES, Sundvall J, Groop PH, Taskinen MR.

Diabetes Care. 2010 Feb;33(2):215-20. doi: 10.2337/dc09-0621. Epub 2009 Oct 21. Erratum in: Diabetes Care. 2010 May;33(5):1151.

PMID:
19846798
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants.

Mychaleckyj JC, Craven T, Nayak U, Buse J, Crouse JR, Elam M, Kirchner K, Lorber D, Marcovina S, Sivitz W, Sperl-Hillen J, Bonds DE, Ginsberg HN.

Diabetes Care. 2012 May;35(5):1008-14. doi: 10.2337/dc11-1811. Epub 2012 Mar 19.

PMID:
22432114
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

Drury PL, Ting R, Zannino D, Ehnholm C, Flack J, Whiting M, Fassett R, Ansquer JC, Dixon P, Davis TM, Pardy C, Colman P, Keech A.

Diabetologia. 2011 Jan;54(1):32-43. doi: 10.1007/s00125-010-1854-1. Epub 2010 Jul 30.

PMID:
20668832
[PubMed - indexed for MEDLINE]
8.

Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience.

Bonds DE, Craven TE, Buse J, Crouse JR, Cuddihy R, Elam M, Ginsberg HN, Kirchner K, Marcovina S, Mychaleckyj JC, O'Connor PJ, Sperl-Hillen JA.

Diabetologia. 2012 Jun;55(6):1641-50. doi: 10.1007/s00125-012-2524-2. Epub 2012 Mar 27.

PMID:
22450889
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.

Keating GM.

Am J Cardiovasc Drugs. 2011 Aug 1;11(4):227-47. doi: 10.2165/11207690-000000000-00000. Review.

PMID:
21675801
[PubMed - indexed for MEDLINE]
10.

Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].

Scott R, Best J, Forder P, Taskinen MR, Simes J, Barter P, Keech A; FIELD Study Investigators.

Cardiovasc Diabetol. 2005 Aug 22;4:13.

PMID:
16111499
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Fenofibrate, homocysteine and renal function.

Foucher C, Brugère L, Ansquer JC.

Curr Vasc Pharmacol. 2010 Sep;8(5):589-603. Review.

PMID:
20507276
[PubMed - indexed for MEDLINE]
12.

Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial.

Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D'Emden MC, Laakso M, Baker JR, Keech AC; FIELD study investigators.

Lancet. 2009 May 23;373(9677):1780-8. doi: 10.1016/S0140-6736(09)60698-X.

PMID:
19465233
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).

Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, DeMicco DA, Fuller JH; CARDS Investigators.

Am J Kidney Dis. 2009 Nov;54(5):810-9. doi: 10.1053/j.ajkd.2009.03.022. Epub 2009 Jun 21.

PMID:
19540640
[PubMed - indexed for MEDLINE]
14.

Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.

Black C, Sharma P, Scotland G, McCullough K, McGurn D, Robertson L, Fluck N, MacLeod A, McNamee P, Prescott G, Smith C.

Health Technol Assess. 2010 Apr;14(21):1-184. doi: 10.3310/hta14210. Review.

PMID:
20441712
[PubMed - indexed for MEDLINE]
Free Article
15.

Fenofibrate: altered renal function.

[No authors listed]

Prescrire Int. 2011 Jun;20(117):154-5.

PMID:
21682015
[PubMed - indexed for MEDLINE]
16.

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A; Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators.

Diabetes Care. 2009 Mar;32(3):493-8. doi: 10.2337/dc08-1543. Epub 2008 Nov 4.

PMID:
18984774
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients.

So WY, Kong AP, Ma RC, Ozaki R, Szeto CC, Chan NN, Ng V, Ho CS, Lam CW, Chow CC, Cockram CS, Chan JC, Tong PC.

Diabetes Care. 2006 Sep;29(9):2046-52.

PMID:
16936151
[PubMed - indexed for MEDLINE]
18.

Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study.

Solini A, Penno G, Bonora E, Fondelli C, Orsi E, Trevisan R, Vedovato M, Cavalot F, Cignarelli M, Morano S, Ferrannini E, Pugliese G; Renal Insufficiency and Cardiovascular Events Study Group.

J Am Geriatr Soc. 2013 Aug;61(8):1253-61. doi: 10.1111/jgs.12381. Epub 2013 Jul 26.

PMID:
23889588
[PubMed - indexed for MEDLINE]
19.

Summarizing the FIELD study: lessons from a 'negative' trial.

Tsimihodimos V, Mikhailidis DP, Elisaf M.

Expert Opin Pharmacother. 2013 Dec;14(18):2601-10. doi: 10.1517/14656566.2013.850075. Epub 2013 Nov 9. Review.

PMID:
24206060
[PubMed - indexed for MEDLINE]
20.

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk